Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from MorphoSys US Inc.

Expert Perspectives in Relapsed/Refractory DLBCL: A Look to the Future of Care

Release Date: June 29, 2020
Expiration Date: June 29, 2021

Activity Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive form of non-Hodgkin lymphoma. The current standard approach remains R-CHOP for newly diagnosed patients; however, approximately 1 of every 2 patients will relapse or have primary refractory disease, making risk assessment crucial to identify patients who will need further interventions. Over the past few years, several novel agents have been approved by the FDA to treat patients with relapsed/refractory DLBCL, with many more targeted therapies under investigation. This rapidly evolving treatment landscape holds promise for improving patient outcomes, yet it can be a challenge to navigate and determine best practices for patient care.

This enduring CME Activity from the live broadcast on June 5, 2020, provides expert perspectives on managing patients with DLBCL, with a focus on emerging therapies for the relapsed/refractory setting. The renowned faculty discussed state-of-the-art approaches in risk stratification and challenges in improving frontline therapy. Although stem-cell transplant plays an important role in the management of these patients, many patients are not candidates for transplant due to age, comorbidities, and other factors, creating a critical unmet medical need. The panel evaluated recent clinical trial data for transplant-ineligible patients with relapsed/refractory DLBCL, including antibodies targeting novel cell-surface antigens, inhibitors of B-cell receptor signaling, and cellular immunotherapy. With a look to the future of care, the expert faculty discussed next steps needed for patients with relapsed/refractory DLBCL to bridge unmet needs, and reviewed related abstracts to be presented at upcoming major society meetings.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from MorphoSys US Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and hematologists involved in the treatment and management of patients with DLBCL. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of DLBCL may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe contemporary treatment strategies in multiple lines of DLBCL care and unmet clinical needs in DLBCL management
  • Examine testing approaches to stratify risk and monitor treatment responses among patients with DLBCL
  • Assess recent efficacy and safety findings from trials designed to evaluate novel approaches for patients with relapsed/refractory DLBCL
  • Explain how recent clinical trial evidence in relapsed/refractory DLBCL can be placed in the context of unmet needs in the field and late-stage ongoing studies in multiple lines of DLBCL care

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Christopher R. Flowers, MD, MS, FASCO
Christopher R. Flowers, MD, MS, FASCO
Professor, Department Chair (Lymphoma/Myeloma)
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: AbbVie, Acerta Pharma, Burroughs Wellcome Fund, Celgene, CPRIT, Eastern Cooperative Oncology Group, Genentech/Roche, Gilead Sciences, Janssen Pharmaceuticals, Millennium Pharmaceuticals/Takeda, National Cancer Institute, Pharmacyclics, TG Therapeutics, V Foundation; Consultant: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche (unpaid), Gilead Sciences, Karyopharm Therapeutics, MEI Pharmaceuticals, Pharmacyclics/Janssen Pharmaceuticals, Spectrum Pharmaceuticals.

Kami Maddocks, MD
Kami Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Columbus, OH

Disclosures: Consultant: Celgene, Karyopharm Therapeutics, MorphoSys, Pharmacyclics, Seattle Genetics.

Grzegorz S. Nowakowski, MD
Grzegorz S. Nowakowski, MD
Program Director, Advanced Hematology Fellowship
Hematology Specialist
Associate Professor
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Celgene/BMS, MorphoSys, Roche; Consultant: Celgene/BMS, Denovo Biopharma, Kite Pharma, Kymera Therapeutics, MorphoSys, Roche; Other: Ryvu Therapeutics (scientific advisory board).

Laurie H. Sehn MD, MPH
Laurie H. Sehn MD, MPH
Chair, Lymphoma Tumour Group
British Columbia Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, British Columbia, Canada

Disclosures: Grant Research Support: Roche/Genentech; Consultant: AbbVie, Acerta Pharma, Amgen, Apobiologix, AstraZeneca, Celgene, Genentech, Gilead, Janssen Pharmaceuticals, Karyopharm Therapeutics, Kite Pharma, Lundbeck Pharmaceuticals, Merck & Co, Morphosys, Roche, Seattle Genetics, Takeda Pharmaceutical Company, Teva Pharmaceuticals, TG Therapeutics, Verastem Oncology.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By